A clinical study of the effectiveness of oral glutamine supplementation during total parenteral nutrition: influence on mesenteric mononuclear cells.
Bacterial translocation (BT) is a well-known insult during total parenteral nutrition (TPN) and a high incidence of morbidity has been reported in septic patients receiving TPN. Inflammatory cytokines were shown to play an important role in the pathogenesis of critical complications following sepsis. Previous studies have indicated that supplementation of TPN with glutamine is effective in preventing BT in animals, but its effectiveness in humans is unclear. The aim of this study was to determine the effectiveness of oral glutamine supplementation to patients receiving TPN in suppressing cytokine production of mesenteric blood mononuclear cells (M-MNC). Fifteen colorectal cancer patients were divided into 3 groups according to preoperative nutrition management. (1) TPN group: TPN with conventional glutamine-free amino acid solution. (2) Gln group: TPN with oral glutamine supplementation of 30 g/d. (3) CONTROL GROUP: oral intake of normal food. M-MNC were obtained immediately after laparotomy and tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10) production of M-MNC was evaluated with or without lipopolysaccharide (LPS) stimulation. TNF-alpha and IL-10 production by LPS-stimulated M-MNC was increased in the TPN group and suppressed in the Gln group. In conclusion, oral glutamine supplementation to patients with TPN was shown to be effective for the prevention of M-MNC activation to avoid excessive production of cytokines.
Aosasa
S
S
Department of Surgery I, National Defense Medical College, Tokorozawa Saitama, Japan.
Mochizuki
H
H
Yamamoto
T
T
Ono
S
S
Ichikura
T
T
D000284:Administration, Oral; D000704:Analysis of Variance; D018988:Bacterial Translocation / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000097:blood / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005973:Glutamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008297:Male; D008643:Mesentery / Q000187:drug effects* / Q000378:metabolism; D008875:Middle Aged; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*; D011300:Preoperative Care; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D014409:Tumor Necrosis Factor-alpha; D005973:Glutamine; D016753:Interleukin-10